Skip to content

Training Cognition in patients with advanced Parkinson's Disease (TrainParC-Advanced) - Feasibility, Effects and Prediction of Responsiveness of a digital cognitive training

Training Cognition in patients with advanced Parkinson's Disease (TrainParC-Advanced) - Feasibility, Effects and Prediction of Responsiveness of a digital cognitive training - TrainParC-Advanced

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00028876
Enrollment
140
Registered
2022-11-21
Start date
2022-11-30
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G20

Interventions

Group 1: 5 week digital cognitive training with HeadApp / NEUROvitalis Group 2: passive wait-list control group

Sponsors

Universität zu Köln
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with IPD according to the UK Brain Bank criteria (Gibb & Lees, 1988). 2. Advanced stage disease, defined as IPD patients who meet = 1 of the 5-2-1 criteria: 5 intakes of levodopa tablets per day and/or 2 hours of "OFF" time per day and/or 1 hour of troublesome dyskinesia per day (Antonini et al., 2018; Santos-García et al., 2020) or receive pump therapy 3. Patients who are cognitively unimpaired or have only suspected MCI (MoCA > 21 points; Dalrymple-Alford et al., 2010) 4. Patients who have stable medication within the last 4 weeks before training and between baseline and posttest 5. Age: 18 years and older; all genders 6. German as native language or sufficiently good knowledge of German 7. Access to a computer, laptop or tablet with internet access

Exclusion criteria

Exclusion criteria: 1. Dementia according to level 1 diagnostics (MoCA < 21 points; Dalrymple-Alford et al., 2010) 2. Major depression (BDI-II = 29 points; Beck et al., 1996). 3. Epilepsy and other diseases with seizure-like manifestations and/or disorders of consciousness (ICD-10 G40) 4. Other neurological or psychiatric illness; acute life-threatening illness (self-report in medical history and physician's letters).

Design outcomes

Primary

MeasureTime frame
Global cognition (MoCA; baseline, posttest + follow-up; measurement procedure administered by a blinded test administrator)

Secondary

MeasureTime frame
Baseline only: cognitive reserve (LEQ; questionnaire) All of the following endpoints will be conducted at baseline, posttest, and 3-month follow-up by a blinded test administrator: 1. neuropsychological measurement procedures to measure specific cognitive functions and fluid intelligence: CERAD plus test battery, BTA, WMS-R forward and backward number span, Benton Judgement of Line Orientation Form H (short version), LPS subtest 4 and subtest 9, ACL auditory language comprehension subtest. 2. measurement of motor skills: UPDRS-III, Hoehn & Yahr, Timed Up and Go 3. questionnaires (self-report): Quality of Life (PDQ-39), Subjective Cognitive Impairment (SCI), Depressive Symptomatology (BDI-II), Fatigue (FSMC), Apathy (AES), Self-Efficacy (SWE), Progression Anxiety (PA-F-KF), Activities of Daily Living (B-ADL), Non-Motor Symptomatology (NMSQ), Fear of Falling (FES), Freezing of Gait (FOG-Q), Sleep Quality (PDSS), Physical activity (PASE)

Countries

Germany

Contacts

Public ContactPaulina Olgemöller

Medizinische Psychologie | Neuropsychologie und Gender Studies, Medizinische Fakultät und Uniklinik Köln, Universität zu Köln

paulina.olgemoeller@uk-koeln.de+4922147877270

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026